Relapsed glioblastomas respond to regorafenib

Data from a phase II trial involving patients with relapsed glioblastoma following chemoradiotherapy, a setting in which few evidence-based therapies are currently available, demonstrate the superiority of the anti-angiogenic tyrosine-kinase inhibitor regorafenib over lomustine chemotherapy. Patients receiving regorafenib had a median overall survival duration of 7.6 months versus 5.6 months in the lomustine group (HR 0.50, 95% CI 0.33–0.75; log-rank P = 0.0009). Grade 3–4 adverse events were more common in the regorafenib group (occurring in 56% versus 40% of patients) and the majority were haematological: decreased platelet count, decreased lymphocyte count and neutropenia were observed in 13%, 13% and 12% of patients, respectively. No treatment-related deaths were reported in either arm. These findings merit further investigation in a randomized phase III trial.


Original article

  1. Lombardi, G. et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet (2018)

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Peter Sidaway.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. Relapsed glioblastomas respond to regorafenib. Nat Rev Clin Oncol 16, 144 (2019).

Download citation